Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.81 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.81 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465014 | 0.89 | SLC2A1 (1.00) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL19183300 | 0.89 | SLC2A1 (1.00) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL6359105 | 0.88 | SLC2A1 (0.64) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL2886267 | 0.82 | SLC2A1 (0.72) | SLC2A1SLC2A4SERPINE1KMT2AESR1 | |
| SCHEMBL17762885 | 0.79 | SLC2A1 (0.52) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL2882328 | 0.78 | SLC2A1 (0.62) | SLC2A1SLC2A4SERPINE1KMT2AESR1 | |
| SCHEMBL10783800 | 0.75 | SERPINE1 (0.62) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL27554704 | 0.73 | SERPINE1 (0.70) | SLC2A1SLC2A4SERPINE1KMT2AESR1 | |
| SCHEMBL3000837 | 0.71 | ESR1 (0.56) | SLC2A1SLC2A4SERPINE1CA12CA1 | |
| SCHEMBL17762883 | 0.71 | SLC2A1 (0.44) | SLC2A1SLC2A4SERPINE1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317068-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY | 2021-10-14 | — | — | US | disclosed |
| US-11072576-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190345094-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY | 2019-11-14 | — | — | US | disclosed |
| US-10385005-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2019-08-20 | — | — | US | disclosed |
| US-9181162-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181162-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317068-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | SLC2A1 1/4885SLC2A4 2/4885SERPINE1 718/4885 |
| US-10385005-B2 | Compositions and methods for glucose transport inhibition | SLC2A1, SLC2A4, SLC2A3 | SLC2A1 1/4885SLC2A4 2/4885SERPINE1 718/4885 |
| US-20190345094-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | SLC2A1 1/4885SLC2A4 2/4885SERPINE1 718/4885 |
| US-11072576-B2 | Compositions and methods for glucose transport inhibition | SLC2A1, SLC2A4, SLC2A3 | SLC2A1 1/4885SLC2A4 2/4885SERPINE1 718/4885 |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | SLC2A1 1/4885SLC2A4 2/4885SERPINE1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.